SAFETY AND EFFICACY OF TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, UP TO 24 MONTHS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: INTERIM DATA FROM OPAL BALANCE, AN OPEN-LABEL, LONG-TERM EXTENSION STUDY

被引：5

作者：

Nash, P. ^{[1
]}

Coates, L. C. ^{[2
]}

Kivitz, A. J. ^{[3
]}

Mease, P. J. ^{[4
,5
]}

Gladman, D. D. ^{[6
]}

Covarrubias-Cobos, J. A. ^{[7
]}

Fleishaker, D. ^{[8
]}

Wang, C. ^{[8
]}

Kudlacz, E. ^{[8
]}

Menon, S. ^{[8
]}

Hendrikx, T. ^{[9
]}

Kanik, K. S. ^{[8
]}

机构：

[1] Univ Queensland, Dept Med, Brisbane, Qld, Australia

[2] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England

[3] Altoona Ctr Clin Res, Dept Rheumatol, Duncansville, PA USA

[4] Swedish Med Ctr, Seattle, WA USA

[5] Univ Washington, Seattle, WA 98195 USA

[6] Univ Toronto, Toronto Western Hosp, Dept Med, Toronto, ON, Canada

[7] Unidad Reumatol Las Amer SCP, Merida, Yucatan, Mexico

[8] Pfizer Inc, Groton, CT 06340 USA

[9] Pfizer Inc, Collegeville, PA USA

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2017年 / 76卷

关键词：

D O I：

10.1136/annrheumdis-2017-eular.1414

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

FRI0509

引用

页码：682 / 682

页数：1

共 50 条

[31] Tofacitinib for the Treatment of Patients with Juvenile Idiopathic Arthritis: An Interim Analysis of Data up to 5.5 Years from an Open-label, Long-term Extension Study
Brunner, Hermine I.
Akikusa, Jonathan
Al-Abadi, Eslam
Bohnsack, John
Boteanu, Alina Lucica
Chedeville, Gaelle
Cuttica, Ruben
De La Pena, Wendy
Jung, Lawrence
Kasapcopur, Ozgur
Kobusinska, Katarzyna
Schulert, Grant
Neiva, Claudia
Rivas-Chacon, Rafael
Rodriguez, Juan Cruz Rizo
Vazquez-Del Mercado, Monica
Wagner-Weiner, Linda
Weiss, Jennifer E.
Wouters, Carine
Suehiro, Ricardo M.
Posner, Holly
Wouters, Ann
Kanik, Keith S.
Luo, Zhen
Martini, Alberto
Lovell, Daniel J.
Ruperto, Nicolino
ARTHRITIS & RHEUMATOLOGY, 2020, 72
[32] Long-term safety and efficacy of tofacitinib up to 48 months in psoriatic arthritis
Strand, Vibeke
LANCET RHEUMATOLOGY, 2021, 3 (04): : E239 - E240
[33] Integrated Efficacy Analysis of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients with Active Psoriatic Arthritis
Nash, Peter
Coates, Laura C.
Fleischmann, Roy
Papp, Kim
Gomez-Reino, Juan J.
Kanik, Keith S.
Wang, Cunshan
Wu, Joseph
Hendrikx, Thijs
Ports, William C.
ARTHRITIS & RHEUMATOLOGY, 2017, 69
[34] INTEGRATED EFFICACY ANALYSIS OF TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
Nash, P.
Coates, L. C.
Fleischmann, R.
Papp, K. A.
Gomez-Reino, J. J.
Kanik, K. S.
Wang, C.
Wu, J.
Hendrikx, T.
Ports, W. C.
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 951 - 952
[35] Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study
Brunner, Hermine I.
Akikusa, Jonathan D.
Al-Abadi, Eslam
Bohnsack, John F.
Boteanu, Alina Lucica
Chedeville, Gaelle
Cuttica, Ruben
De La Pena, Wendy
Jung, Lawrence
Kasapcopur, Ozgur
Kobusinska, Katarzyna
Schulert, Grant S.
Neiva, Claudia
Rivas-Chacon, Rafael
Rizo Rodriguez, Juan Cruz
Vazquez-Del Mercado, Monica
Wagner-Weiner, Linda
Weiss, Jennifer E.
Wouters, Carine
Posner, Holly
Wouters, Ann
Chang, Cheng
White, Claire
Kanik, Keith
Liu, Shixue
Martini, Alberto
Lovell, Daniel J.
Ruperto, Nicolino
ANNALS OF THE RHEUMATIC DISEASES, 2024, 83 (11) : 1561 - 1571
[36] Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study
Brunner, Hermine I.
Akikusa, Jonathan D.
Al-Abadi, Eslam
Bohnsack, John F.
Boteanu, Alina Lucica
Chedeville, Gaelle
Cuttica, Ruben
De La Pena, Wendy
Jung, Lawrence
Kasapcopur, Ozgur
Kobusinska, Katarzyna
Schulert, Grant S.
Neiva, Claudia
Rivas-Chacon, Rafael
Rizo Rodriguez, Juan Cruz
Vazquez-Del Mercado, Monica
Wagner-Weiner, Linda
Weiss, Jennifer E.
Wouters, Carine
Posner, Holly
Wouters, Ann
Chang, Cheng
White, Claire
Kanik, Keith
Liu, Shixue
Martini, Alberto
Lovell, Daniel J.
Ruperto, Nicolino
ANNALS OF THE RHEUMATIC DISEASES, 2024, 83 (11) : 1561 - 1571
[37] TOFACITINIB, AN ORAL, SMALL MOLECULE JANUS KINASE INHIBITOR, IN THE TREATMENT OF ULCERATIVE COLITIS: ANALYSIS OF AN OPEN-LABEL, LONG-TERM EXTENSION STUDY WITH UP TO 5.9 YEARS OF TREATMENT
Lichtenstein, Gary R.
Loftus, Edward V.
Wei, Shu Chen
Damiao, Aderson O.
Judd, Donna
Lawendy, Nervin
Chan, Gary
Zhang, Haiying
Wang, Wenjin
Thorpe, Andrew J.
Bloom, Stuart
GASTROENTEROLOGY, 2020, 158 (06) : S1190 - S1191
[38] Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study
Papp, Kim A.
Krueger, James G.
Feldman, Steven R.
Langley, Richard G.
Thaci, Diamant
Torii, Hideshi
Tyring, Stephen
Wolk, Robert
Gardner, Annie
Mebus, Charles
Tan, Huaming
Luo, Yingchun
Gupta, Pankaj
Mallbris, Lotus
Tatulych, Svitlana
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : 841 - 850
[39] Long-term Safety of Filgotinib in Patients with Psoriatic Arthritis, Week 52 Safety Data from a Phase 2 Open-Label Extension Study
Coates, Laura
Mease, Philip
Gladman, Dafna
Van den Bosch, Filip
Rychlewska-Hanczewska, Anna
Tasset, Chantal
Meuleners, Luc
Trivedi, Mona
Gao, Jingjing
Besuyen, Robin
Helliwell, Philip
ARTHRITIS & RHEUMATOLOGY, 2019, 71
[40] Long-Term Safety of Filgotinib in Patients with Psoriatic Arthritis, Week 52 Safety Data from a Phase 2 Open-Label Extension Study
Gladman, Dafna
Coates, Laura
Mease, Philip
van den Bosch, Filip
Rychlewska-Hanczewska, Anna
Tasset, Chantal
Meuleners, Luc
Trivedi, Mona
Guo, Ying
Besuyen, Robin
Helliwell, Philip
JOURNAL OF RHEUMATOLOGY, 2020, 47 (07) : 1066 - 1067

← 1 2 3 4 5 →